Figure 2: Mesothelin-targeted TR3 protects its target cells from cell death. | Scientific Reports

Figure 2: Mesothelin-targeted TR3 protects its target cells from cell death.

From: Membrane-proximal TRAIL species are incapable of inducing short circuit apoptosis signaling: Implications for drug development and basic cytokine biology

Figure 2

(a) Representative example of Jurkat-Meso cell enrichment following SS-TR3 drug exposure. The cells were treated with SS-TR3 for six days or with medium alone (ctrl), followed by assessing the percentage of mesothelin-positive cells by flow cytometry. (b) Graphic representation of the data shown in (a) (n = 3, mean ± SEM; ****P < 0.0001, t-test). (c) Jurkat-Meso cells (~8%) do not acquire a growth advantage following treatment with SS-TR3 (CFSE dilution assay without apoptosis blockade) (n = 3, mean ± SEM; ns, not significant, t-test). (d) Jurkat-Meso cells do not expand following SS-TR3 treatment in the presence of pan-caspase inhibition (Z-VAD-FMK) (n = 3, mean ± SEM; ns, not significant, ****P < 0.0001, one-way ANOVA).

Back to article page